German start-up secures backing for smart epilepsy wearable programme

A German start-up has received funding to develop smart wearable devices aimed at people with epilepsy, news-medical.net reports.

The size of the funding round, the names of the investors and the device specifications have not been disclosed in the initial reporting. What the brief announcement confirms is the company's product direction: wearables intended for the epilepsy population — a category that includes wristbands, headbands, patches and in-ear devices recording biosignals relevant to seizure detection.

What does "smart" mean in epilepsy wearables?

Most investigational and commercial epilepsy wearables rely on one of three recording modalities: surface electroencephalography from dry or gel-free scalp electrodes embedded in a headband or in-ear device; electrodermal activity and accelerometry from a wristband; or single-channel electrocardiography tracking heart-rate variability tied to autonomic seizure signatures.

Multimodal devices that combine surface EEG, EMG, ECG and motion sensors have generated the strongest published performance for generalised tonic-clonic seizure detection, with sensitivities reported in several series between 90% and 95% and false-alarm rates below one event per 24 hours. Subdermal EEG patches recording beneath the scalp have also entered first-in-human trials as a longer-wear alternative to scalp electrodes.

The "smart" label is commonly applied to devices that run on-device machine-learning classifiers rather than streaming raw biosignals to a phone or cloud for interpretation.

Why does portable monitoring matter clinically?

Continuous outpatient EEG remains rare outside specialised epilepsy monitoring units. Wearables extend recording into daily life, where most seizures occur unwitnessed and where patient-reported seizure diaries underestimate true frequency.

Clinicians and regulators have approached seizure-detection wearables with caution. The FDA cleared the first device — Embrace by Empatica — for adjunctive seizure monitoring in 2018, with subsequent 510(k) clearances for wrist-worn detectors of generalised tonic-clonic seizures. None of those devices is approved for diagnosing epilepsy, replacing video-EEG in the EMU, or titrating therapy automatically.

For refractory focal epilepsy, the RNS System (NeuroPace) remains the only FDA-approved closed-loop intracranial device, using ECoG-based detection at the seizure onset zone to trigger stimulation. Wearable closed-loop therapy is still investigational.

What remains to be confirmed about this funding round?

The available reporting identifies the company only as a German start-up. The founders, lead investor and funding amount are unstated, as is the target seizure type and the device form factor.

For clinical neurophysiology readers, the points worth tracking are:

• whether the device is positioned as a medical-grade Class IIa or IIb product under the EU MDR or as a wellness device
• which seizure types the classifier targets
• whether validation studies will enrol adults or include paediatric cohorts

If the company follows the published development path for seizure-detection wearables, regulatory submission under the EU MDR rather than the US FDA 510(k) route would align with its German base. A pivotal validation study against video-EEG in an epilepsy monitoring unit is the typical next milestone before any CE mark claim.

The wider field continues to test whether wearable seizure detection can move from adjunctive flagging of tonic-clonic events to reliable detection of focal impaired-awareness seizures — the most common seizure type in adults with drug-resistant epilepsy and the hardest to capture outside the EMU.